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Abstract
Background: Remission is a common outcome of short-term trials and the main goal of acute and longterm
treatment. The longitudinal stability of remission has rarely been investigated under naturalistic treatment
conditions.
Methods: Naturalistic multisite follow-up study. Three-year symptomatic long-term outcome of initially hospitalized
tertiary care patients (N = 784) with major depressive episodes. Remission rates as well as the switch rates between
remission and non-remission were reported.
Results: After one, two and three years 62 %, 59 % and 69 % of the observed patients met criteria for remission.
During the follow-up 88 % of all patients achieved remission. 36 % of maintained remission from discharge to 3-
years, 12 % of all patients never reached remission and 52 % percent showed a fluctuating course switching from
remission to non-remission and vice versa. There was considerable transition between remission and non-remission.
For example, from discharge to 1 year, from 1 to 2, and from 2 to 3 years 25 %, 21 % and 11 % lost remission.
Conclusion: Cumulative outcome rates are encouraging. Absolute rates at predefined endpoints as well as the
fluctuations between these outcomes reflect the variable and chronic nature of major depression.
Background
Drug approval authorities like the European Medicines
Agency demand that clinical relevant outcome criteria like
remission should be used in antidepressant short-term tri-
als [1]. Also in clinical practice remission, commonly de-
fined as the virtual absence of depressive symptoms, is
still one of the main goals of acute antidepressant treat-
ment [2, 3]. Evidence from naturalistic long-term studies
of depressed inpatients suggests that up to 90 % achieve a
full remission over a 2–5 year period [4–8]. In addition,
remitted patients experience significantly lower relapse
rates [9, 10].
On the other hand, it is known that the nature of de-
pression is rather unstable: Symptoms improve and
worsen over time and patients can switch between a
symptomatic and a remitted state [10, 11, 12, 13]. How-
ever, the stability of remission so far has only rarely been
reported. Most long-term reports tend to focus either on
cumulative remission rates or on relapse rates, but do
not report how many patients develop symptoms again
and leave the remitted state after a certain period. Thus,
the fluctuations inherent in major depressive disorder
can easily be missed and cumulative remission rates
might lead to an overestimation of positive outcome in
major depression. Moreover, the majority of results on
remission relies on data from randomized controlled tri-
als with limited generizability with respect to a real
world settings [4–8].
With regards to inpatient treatment our group re-
cently reported that among a representative sample of
tertiary care inpatients (N = 1014) with major depressive
episode more than 50 % of all patients reached remission
at discharge [14, 15].
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Here we present the 3-year long-term results of this
prospective, multicentre follow-up trial on inpatients
with major depressive disorder. This cohort was
followed up annually after discharge from inpatient
treatment with attention to course and outcome of the
major depressive disorder. The current report comple-
ments the description of the acute inpatient outcome.
Relapse rates and risk factors have already been reported
in a companion paper [10].
In this report we specifically aimed at investigating the
rates and the stability of remission at the 1, 2 and 3 year
follow-up. Additionally we sought to investigate how
many patients never remit from discharge on and to get
an estimate of the antidepressant treatment level during
the follow-up.
Methods
Study overview and organization
This prospective naturalistic multicenter follow-up was
primarily designed to address the issues of treatment re-
sistance, relapse, chronicity and suicidality in depressive
disorders within the framework of psychiatric university
and district hospitals. It was part of the German research
network on depression (GRND) and was funded by the
German Federal Ministry of Education and Research
(BMBF). The study was planned to be conducted in repre-
sentative inpatient groups and settings using clinical man-
agement tools that easily can be applied in daily practice.
The follow-up consisted of two parts: a) the naturalis-
tic acute inpatient treatment period with biweekly mea-
surements [14], which was followed by b) a long-term
naturalistic follow-up lasting up to 3 years after dis-
charge. Here, results of the three year follow-up were
presented. Twelve study centers across Germany partici-
pated in this trial, including seven university hospitals
(Berlin: Campus Charité Mitte and Campus Benjamin-
Franklin, Düsseldorf, Halle, Heidelberg, Munich: MPI
and LMU) and five district hospitals (Gabersee, Inn-
Salzach-Clinic/Bavaria, Haar, Isar-Amper-Clinic/Bavaria,
Berlin: Auguste-Viktoria-Hospital, St.-Joseph-Hospital
and St.-Hedwig-Hospital). Clinical research coordinators
at each site assisted in protocol implementation and
computerized data collection.
Experimental procedures
Sample and data collection
The diagnose of a depressive spectrum disorder accord-
ing to DSM-IV was confirmed at baseline and at dis-
charge at the end of the acute phase and at each annual
follow-up visit using the Structured Clinical Interview
for DSM-IV (SCID-I) [16]. SCID II was applied to care-
fully assess comorbid axis II personality. To allow inclu-
sion of clinical representative populations the following
inclusion and exclusion criteria was applied:
Inclusion criteria were:
1) Age between 18 and 65
2) Signed written informed consent
3) Hospitalization and fulfilling of ICD-10 diagnostic
criteria for any major depressive episode (ICD-10:F32,
F33, F34, F38) or for a depressive disorder not
otherwise specified (ICD-10: F39) as primary diagnosis.
Exclusion criteria were:
1) Organic cause of depression
2) Insufficient knowledge of German language
3) Distance from place of residence to the study center
of more than 100 km
The 3-year follow-up period started after discharge
from inpatient treatment.
The annual follow-up ratings further included, the
Hamilton Depression Rating Scale, (HAMD-17) [17], the
MADRS [18] and the collection of socio-demographic
and clinical variables using the systematic basic assess-
ment scale of clinical and socio-demographic variables
in psychiatry (BADO) [19]. These methods were de-
scribed in detail in a study protocol, which allowed post-
hoc analyses. The respective local Ethics Review
Committee of each participating site has approved the
study protocol. Signed written informed consent was ob-
tained from all participants.
Treatment
During the follow-up, patients were treated naturalistic-
ally at the discretion of the respective outpatient psych-
iatrist/neurologist, family doctor or general practitioner
in charge. All medication decisions including medication
discontinuation and switches were made by the respect-
ive physicians. Treatment was recorded as prescribed
medication class at each follow-up visit.
Outcome criteria
HAMD-17 and MADRS total scores were calculated for
all follow-up visits. Remission was defined as HAMD-17
total score ≤ 7 [20].
Statistical analysis
In order to assess if drop-outs were at random, group
comparisons between drop-outs after one year and the 3-
year follow up sample were conducted using Fisher’s exact
test, in case of categorical data and Wilcoxon-Mann-
Whitney-U test in case of metrical data, respectively.
In order to account for the comparably high dropout
rate we looked at two different samples 1) The LOCF
sample with a total number of 784 patients at each visit
and 2) The completer sample (=observed case analysis,
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OC) of 148 patients, with visits at each follow-up. Due
to the exploratory character of these group comparisons
there is no multiple testing problem and therefore no re-
spective corrections have been performed.
All statistical analyses were performed using the statis-
tical software environment R 2.11.1 [21].
Results
Patient disposition
Detailed description of patient disposition of the acute
treatment phase can be found elsewhere [14]. The num-
bers of patients eligible for follow-up analysis at baseline,
at 1, 2 and 3 years are displayed in the flow chart in Fig. 1.
Of all (n = 1073) enrolled patients 1014 patients had
complete baseline HAMD ratings. At discharge 784 pa-
tients entered into the 3-year follow-up phase. During
the 3-year follow-up phase 641 (82 %) patients withdrew
from the follow-up. The reasons included withdrawal of
consent (n = 235), lost to follow-up (n = 317, death (n = 16,
8 = cardiovascular events, 2 = cerebrovascular events,
2 = pneumonia, 3 = suicide, 1 = cancer) patients moving
into a different town (n = 34), difficulties coming to the
study visits (n = 23).
Patients remaining in the follow-up sample were sig-
nificantly more women, had lower rates of personality
disorders, were less often referred to inpatient treatment
due to suicidality, were more often living in a relation-
ship, were less often discharged against medical advise,
were longer hospitalized and had higher HAMD-17
baseline scores (Table 1).
Depression ratings
Remission rates, HAMD-17 and MADRS mean scores
for observed case analysis and last observation carried
forward method are summarized in Table 2.
Remission
Remission rates at discharge 1- ,2- and 3-year follow-up
were 54 %, 55 %, 56 % and 58 %, respectively (LOCF).
Completer analysis showed remission rates of 64 %,
62 %, 59 % and 69 % (Table 2).
According LOCF 86 %, 93 % and 98 % maintained re-
mission after one, two and three years. And only 14 %,
7 % and 2 % switched to non-remission after one, two
and three years (Fig. 2).
In the completer sample the remission status was con-
stant in 75 %, 79 % and 89 % after one, two and three
years. 25 %, 21 % and 11 % switched to non-remission
from the preceding to the following year after 1, 2 and
3 years (Fig. 3).
Illness course
67 % of all discharged patients remitted symptomatically
at some time point during the 3-year follow-up and
43 % maintained remission, 33 % never reached a remit-
ted state, whereas 24 % had a fluctuating course (LOCF).
In the completer sample 88 % remitted at some time
point during the 3 year period, only 36 % of all patients
maintained their remission status throughout all visits,
12 % did never remit and 52 % showed a fluctuating
course (OC) (Table 3).
Treatment
In order to get an estimate for the development of the
prescribed medication and treatment we relied on the
observed cases (OC) of 143 patients.
At discharge 96.3 % of 143 patients had at least one
antidepressant, at three year follow-up still 70.4 % of all
patients were taking a minimum of one antidepressant,
whereas 21.4 % were taking no psychopharmacologic
medication at all. Of the 70.4 % patients taking antide-
pressants, 23.8 % got TCAs, 21.4 % SSRIs and 28 % got












Acute Inpatient Phase Follow-Up
Fig. 1 Flow-chart for patients showing the number of available patients
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dual acting antidepressants (either venlafaxine or mirta-
zapine) and 6.4 % received MAO inhibitors (Fig. 4).
Apart from atypical antipsychotics (rising form 6.5 % at
discharge to 14.9 % at 3-year follow-up) the prescription
rates of all other medication classes declined. Benzodiaze-
pines and tranquilizers showed the largest decline (from
51.9 % at discharge to 13.0 % at 3-year follow-up), followed
by declining rates of patients receiving psychotherapy (from
81.5 % to 30.6 % at 3-year follow-up).
Discussion
In this report we applied a descriptive approach and fo-
cussed on remission rates and its stability for a series of
depressed subjects for a period of 3-years.
Cumulative remission rates
From that perspective the outcome looks quite promis-
ing: 67 % of the LOCF sample and most patients of the
OC (88 %) sample recovered at some time point during
three years (cumulative remission rate). These cumula-
tive rates are in a comparable range to other naturalistic
long-term follow-ups. Holma found 88.5 % after 5 years,
O’Leary 88 % after 3 years and Ramana 80 % after 2 years
[4, 6, 7]. Also the landmark study by Keller about the
naturalistic 5-year course of 431 subjects with major de-
pression found cumulative recovery rates (defined as 8
consecutive weeks with no or minimal symptoms) of
70 % after 1 year, 81 % within 2 years, 87 % within
4 years and 88 % within 5 years [8].
Absolute response and remission rates
In contrast to cumulative rates, absolute remission rates
at a certain follow-up time tend to be considerably
lower. With respect to remission rates after one, two
and three years, the LOCF analysis revealed 55 %, 56 %
and 58 % of remitters in the present study. With respect
to observed cases after one, two and three years, almost
62 % completer after one, (59 %) after two and (69 %)
after three years met criteria for remission (OC).
The naturalistic Vantaa sample comprised 163 outpa-
tients (OC sample) and applied DSM-IV criteria over a
continuous period of two months [4]. After five years
50 % of the observed cases were in full remission in this
follow-up study.
The MADRS remission rates of observed cases
(MADRS < 9) of the naturalistic SLICE study on a pri-
mary care population (n = 1031) after 1- (70.7 %) and 2-
years (75.3 %) were higher than in the present report
Table 1 Differences between patients lost to follow-up (drop-outs) and the completer sample
Drop-out (n = 641) Completer (n =143) OR p-value
Female 375 (59 %) 96 (67 %) 1.39 0.017
Positive family anamnesis 241 (38 %) 59 (41 %) 1.12 0.42
Recurrent depression 337 (53 %) 84 (59 %) 1.24 0.11
Any personality disorder 260 (41 %) 44 (31 %) 0.64 0.043
Suicidality admission reason 337 (53 %) 61 (43 %) 0.66 0.001
Living with a partner 248 (39 %) 81 (57 %) 2.04 <0.001
Discharged against medical advise 64 (10 %) 7 (5 %) 0.47 0.009
Number of hospitalisations before admission 0 ± 2.00 (0–21) 0.5 ± 2.00 (0–15) 0.15
Inpatient treatment time (days) 49 ± 47.50 (1–278) 56 ± 46.00 (1–363) 0.007
Age 44.4 ± 12.30 (18.2–69.6) 45.7 ± 11.70 (18.6–65.9) 0.1
Age at onset 38.1 ± 12.81 (10–69) 38.3 ± 12.61 (9–65) 0.89
HAMD 17 baseline 22.8 ± 5.88 (2–40) 21.7 ± 6.08 (1–40) 0.005
HAMD 17 discharge 7.8 ± 5.79 (0–31) 7.7 ± 5.46 (0–30) 0.77
Table 2 MADRS and HAMD total scores (and standard deviation) and proportion of responders (50 % HAMD-17 baseline reduction)
and remitters (HAMD-17≤ 7) at discharge, year 1, year 2 and year 3: last observation carried forward and completer analysis
N DISCHARGE YEAR 1 YEAR 2 YEAR 3
Remission rate (LOCF) 423 (54 %) 431 (55 %) 436(56 %) 451 (58 %)
Remission rate (OC) 92 (64 %) 89 (62 %) 84 (59 %) 99 (69 %)
HAMD-17 (LOCF) 8.8 (±6.8) 7.4 (±7.4) 6.3 (±6.8) 6.6 (±6.8)
HAMD-17 (OC) 7.6 (±5.9) 7.2 (±7.8) 7.1 (±7.4) 6.1 (±6.4)
MADRS (LOCF) 12.5 (±7.6) 10.9 (±9.9) 10.6 (±10.1) 10.6 (±10.1)
MADRS (OC) 11.9 (±6.8) 9.4 (±11.2) 9.3 (±10.8) 8.3 (±9.6)
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[22]. But it needs to be considered, that a primary out-
patient sample usually includes less severe and less re-
fractory patients in comparison to a tertiary care
inpatient population as in the report at hand [23].
The PROSPECT study reported HAMD-17 remission
rates of the observed cases of an intervention group re-
ceiving algorithm-based interventions of 40.1 % after
one and of 49.7 % after two years although the mean
HAMD baseline severity (18.1 vs. 24), was only in a
moderate range [24].
Thus, all in all the rates of the present report are in a
similar range to other naturalistic data with a tendency
towards the upper range, despite its tertiary referral in-
frastructure. An important limitation in that context is
the high drop-out rate of 82 % leading to a selection of
patients with favourable outcomes (also see limitations).
Although “real world” patients and patients included
in randomized controlled trials are not easily compar-
able [25, 26], a look into long-term data of a recent ran-
domized controlled trial, might still be informative. For
example in the Co-Med trial remission rates after 7-
months were lower with 48 % (LOCF). But here the
observational period was shorter and the remission cri-
terion stricter (patients had to be in a remitted state on
2 consecutive visits) [27]. Another example is the PRE-
VENT trial, here the remission rates of this double blind
randomized controlled long term trial comparing fluox-
etine against venlafaxine (N = 268) were higher at year
one (67–68 %) and (71 %–77 %) at year two (OC) [28].
Stability of remission and illness course
The stability of remission for LOCF and OC analysis is
illustrated in flow chart diagrams (see Figs. 2 and 3).
Due to the high drop-out rate, the OC analysis seems to
be the most reliable one in that respect (see limitations).
The highly fluctuating course of major depressive dis-
order is reflected by 52 % of patients (OC) showing a
fluctuation from remission to non-remission and vices
versa throughout the three years. This result is in line to
the previously published corresponding relapse rates
which have been retrospectively assessed at each follow-
up. Of the 458 patients 155 (33.6 %) experienced at least
one severe relapse during the 3-year follow-up period.
The highest rate was found in the first month and the
first year (25.3 %) after discharge from inpatient treat-
ment declining to 16.1 % two years thereafter [10].
A finer grained picture can be obtained by only look-
































Fig. 2 The year to year movement from discharge on until the end of the 3-year follow-up of patients being in HMAD-17 remission (dark) or
non-remission (light) for the LOCF sample (N = 784). The width of the arrows corresponds to the magnitude of the percentage. For example, from
discharge to year one 86 % stayed in remission whereas 82 % stayed non-remitters. 14 % of non-remitted patients became remitters and 18 % of
remitted patients lost remission at the 1-year follow-up
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These rates vary between 11 % and 25 % with 45 % loos-
ing remission at some time point during the three years.
Only 36 % of all patients (and 55 % of initially remitted
patients) stayed in remission during the whole time
(OC). The recent naturalistic PREDICT-NL study
followed 174 primary care outpatients with major de-
pressive disorder (out of 1338 attendants) for a period of
three years. In line with our results the authors found a
rate of 40 % with a fluctuating course and rate of 43 %
staying in remission right from the start. The benign
rates can again be well explained by the milder and less
complex cases of a primary care outpatient population.
However, still 17 % of patients in the PREDICT-NL
study had a chronic course and stayed in an episode for
the whole 3 years [26]. In the report at hand, 12 % of all
discharged patients stayed in non-remission from
discharge up to 3-years and thus had a chronic course
(OC, Table 3). This level of chronicity is also in accord-
ance with earlier reports. Keller reported that 12 % pa-
tients of the CDS study did not reach recovery after
5 years [9]. Likewise Jules Angst reported in his 21 year
follow-up of 406 initially hospitalized patients that 13 %
of all patients developed a chronic course [27]. Spijker
found a slightly higher rate of 20 % of patients with
MDD who had not fully recovered after a period of two
years in the NEMESIS study [29].
Treatment
After three years 70.4 % of the completer sample re-
ceived at least one antidepressant. A recent systematic
review including 14 large observational naturalistic/epi-
demiologic surveys reported adherence rates ranging
from 30–97 % (median 67 %) [30]. The comparably high
psychotherapy rate as well as the high rate of patients
being in specific mental health care (84 % year one,
81 % year two and 78 % year three), together with a
higher chance of adherent patients staying in the com-
pleter sample might have led to high adherence rates in
the completer sample. In addition it should be kept in

































Fig. 3 The year to year movement from discharge on until the end of the 3-year follow-up of patients being in HMAD-17 remission (dark) or
non-remission (light) for the OC sample (N = 143). The width of the arrows corresponds to the magnitude of the percentage. For example, from
discharge to year one 75 % stayed in remission whereas 61 % stayed non-remitters. 39 % of non-remitted patients became remitters and 25 % of
remitted patients lost remission at the 1-year follow-up
Table 3 Total numbers (%) of patients remaining remitters/no
remitters/respondents/no respondents after three years: last
observation carried forward and completer analysis
LOCF OC
Remission 337 (43 %) 51 (36 %)
No Remission 259 (33 %) 17 (12 %)
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healthcare insurance for all community members, allowing
a free choice of doctor. Therefore, the encouraging adher-
ence rates can partly be traced back to specialized mental
health care advanced by the German insurance policy.
Limitations
The most important limitation pertains to the high
dropout rate. Attrition rates in long-term studies of
similar time spans, range from 18 % [31], to 72 % [32,
33]. The Texas algorithm project showed similar attrition
rate after one year of 47 % [34]. Thus, the three-year attri-
tion rate of the present study of about 82 % of the patients
entering the follow-up appears to be within a high range.
Amongst others, one reason for the high attrition rate
in the study at hand may have been due to the way par-
ticipants during the follow-up had to be contacted in ac-
cordance with the study protocol. Participants were only
allowed to be contacted via letters and not via telephone
or email. Thus, over the three years twenty mailing
waves have been performed. In addition, no telephone
interviews were intended for the yearly visits but face to
face interviews had to be performed instead. Although
these interviews might result on the one hand in a
higher data quality, they may led to higher attrition rates
on the other hand. For future studies contact via Email
and especially telephone calls, which have shown to in-
crease retention time in trials are clearly preferable [35].
The drop out analysis revealed that patients staying up
to three years in the follow up exhibited variables that
are associated with better longterm outcome (female
gender, less comocrbid personality disorders, living more
often with partner, less often discharged against medical
advice, longer inpatient treatment time, lower Hamilton
baseline score, (Table 1)).
These variables are largely in line with the variables as-
sociated with lower attrition in the STAR*D Study and
the Texas algorithm project [34]. Patients of the drop
out sample showed significantly lower remission rates in
step one and two of STAR*D [34, 36]. Thus the outcome
of the OC sample of the report at hand are if anything
optimistic and it seems likely that we have overestimated
positive outcome[37, 38].
Nevertheless, this sample of 3-year long-term data of
initially hospitalized, naturalistic treated and extensively
reevaluated patients with major depression is still one of
the largest European follow-ups.
Since there were broad inclusion and only few exclu-
sion criteria, patients who would have been excluded in
most randomized controlled trials, were included in our
study. This is a limitation and strength at the same time.
The results of this study could be more generalizable to
routine clinical practice and exert high external validity
for adult inpatients with major depressive disorder. On
the other hand internal validity is reduced due to the
lack of any control group. Therefore conclusions regard-
ing treatment effects are very limited. In addition these
results might not be easily generizable to outpatient
populations or elderly patients [39].
We also strictly focused on remission on certain points
in time without applying any duration thresholds. Sev-
eral authors suggested that a patient should at least
remain in remission for at least 8 consecutive weeks
before he can be considered as recovered [2, 9]. More-
over, since there was no course interview implemented,
we cannot rule out that a patient who is in remission at
all three visits may have experienced episodes or more
illness activity in between the visits. Thus our rates of

































Fig. 4 Naturalistic treatment of patients at discharge and after 1, 2 and 3 years of follow-up, the data presented here relates to the 3-year
completer sample (OC, N = 143)
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measures like ecological momentary assessment tech-
niques (EMA) could provide promising tools which
might complement such traditional outcomes measures.
Thus, in summary the results of the 3-Year completer
sample, even if positively biased, are rather disappointing
with 12 % showing a chronic course, 52 % a highly fluctu-
ating course and only 36 % percent a stable remission and
call for future strategies enhancing long-term outcome.
A comment on missing data in long-term trials - Last
observation carried forward (LOCF) and observed cases (OC)
Valid analyses of longitudinal data are complex and diffi-
cult, especially if data are missing for reasons that are re-
lated to the outcome. We used two traditional methods
to address this problem: 1) the LOCF method which im-
putes data by carrying the last observation forward and
2) the completer or observed case analysis by only in-
cluding those patients who had an observation at each
visit and at endpoint. It is often argued that the bias in
LOCF leads to a “conservative” (under-) estimation of
treatment effects. On the other hand, the completer ana-
lysis or observed case analysis is assumed to lead to an
overestimation of treatment effects. Therefore a com-
bined approach can help to get a realistic idea of the
outcome rates.
In the present study LOCF indeed estimated absolute
remission at the predefined time points rates more con-
servatively but overestimated the stability over the long
term course due to the high rate of patients lost to
follow-up. For example stable remitters were higher in
the LOCF analysis than with the OC method (43 %,
LOCF vs 36 % OC). In contrast, the observed case ana-
lysis showed less conservative absolute outcomes (e.g.
yielding higher remission rates after 1, 2 and 3 years)
but allows a more realistic look on the development over
the long term course.
In recent years modern imputation methods like mixed
models for repeated measures are becoming more and
more common and are often recommended as preferable
method. On the other hand it has been emphasized that
they are not the cure for all problems associated with
missing data [40, 41].
Conclusion
The present results may reflect clinical wisdom and ex-
perience that patients with major depression have an in-
herent tendency to recover and that we can reassure our
patients that in the long run almost all patients will ex-
perience a significant symptom reduction. But on the
other side a significant percentage will again become
more symptomatic in the long run. Thus major depres-
sive illness appears to have a highly unstable and fluctu-
ating course. Furthermore, 12 % of patients did not
remit initially and did not reach remission by the end of
the study. The persistence of significant levels of psycho-
pathology is associated with significant psychosocial im-
pairment and calls for long-term treatment intervention
studies addressing this unmet need.
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